# Alternative Dosing of Eltrombopag for the Treatment of Chronic, Steroid-Refractory Immune Thrombocytopenia

## TL;DR

A 72-year-old man with chronic, steroid-resistant ITP responded well to biweekly eltrombopag, suggesting this dosing could be effective and easier to manage.

## Contribution

Biweekly eltrombopag dosing is proposed as an effective alternative for chronic, steroid-refractory ITP.

## Key findings

- Biweekly eltrombopag dosing achieved platelet response comparable to daily dosing.
- The approach may improve adherence and reduce financial burden for patients.
- This case suggests less frequent dosing could be a viable treatment strategy.

## Abstract

Idiopathic thrombocytopenic purpura (ITP) presents challenges in management, particularly in cases refractory to corticosteroids. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, offer alternative therapeutic options. We report a case of a 72-year-old South Asian male with steroid-refractory chronic ITP who achieved a favorable response with biweekly eltrombopag dosing. Platelet response was comparable to daily dosing, suggesting the efficacy of less frequent administration schedules. This approach may enhance patient adherence and reduce treatment-related financial burdens. Biweekly eltrombopag dosing presents a promising alternative for chronic ITP management, warranting further investigation.